Xilio Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
Xilio Therapeutics Free Cash Flow (FCF) History (XLO)
Xilio Therapeutics reported −$5.5M in free cash flow for fiscal 2025, an increase of $12.9M from the previous fiscal year, with a free cash flow margin of −12.59%.
View full Xilio Therapeutics company overviewXilio Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$5.5M | $12.9M | — | −12.59% |
| 2024 | 2024-12-31 | −$18.4M | $50.7M | — | −290.26% |
| 2023 | 2023-12-31 | −$69.1M | $8.5M | — | — |
| 2022 | 2022-12-31 | −$77.6M | $4.3M | — | — |
| 2021 | 2021-12-31 | −$81.9M | −$43.6M | — | — |
| 2020 | 2020-12-31 | −$38.3M | — | — | — |
Xilio Therapeutics quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$18.8M | −$3.9M | — | −100.48% |
| Q1 2026 | 2026-03-31 | −$22.9M | −$51.9M | — | −181.05% |
| Q4 2025 | 2025-12-31 | −$2.1M | $11.6M | — | −15.29% |
| Q3 2025 | 2025-09-30 | −$17.5M | −$4.1M | — | −91.76% |
| Q2 2025 | 2025-06-30 | −$14.9M | −$1.5M | — | −184.04% |
| Q1 2025 | 2025-03-31 | $29.0M | $45.8M | — | +988.26% |
| Q3 2024 | 2024-09-30 | −$13.7M | $11.7M | — | −604.55% |
| Q4 2023 | 2023-12-31 | −$13.4M | $5.3M | — | — |
| Q3 2023 | 2023-09-30 | −$13.4M | $6.9M | — | — |
| Q2 2023 | 2023-06-30 | −$16.9M | $637,000 | — | — |
| Q1 2023 | 2023-03-31 | −$25.4M | −$4.3M | — | — |
| Q4 2022 | 2022-12-31 | −$18.7M | −$1.2M | — | — |
| Q3 2022 | 2022-09-30 | −$20.2M | $591,000 | — | — |
| Q2 2022 | 2022-06-30 | −$17.5M | $3.0M | — | — |
| Q1 2022 | 2022-03-31 | −$21.1M | $1.8M | — | — |
| Q4 2021 | 2021-12-31 | −$17.5M | — | — | — |
| Q3 2021 | 2021-09-30 | −$20.8M | — | — | — |
| Q2 2021 | 2021-06-30 | −$20.6M | — | — | — |
| Q1 2021 | 2021-03-31 | −$22.9M | — | — | — |
Xilio Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$38.3M to −$5.5M, a net increase of $32.8M. Xilio Therapeutics's latest reported quarter, Q2 2026, generated −$18.8M in free cash flow, a decrease of $3.9M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Xilio Therapeutics filings at SEC.gov ↗